Unusually, a takeover rumor was confirmed when US company Allergan Inc said it had been having talks with newly-created Swedish-American group Pharmacia & Upjohn. However, a spokesman for P&U questioned by the Marketletter kept to the traditional line of "no comment" on rumors.
The "confirmation," if that is what it can be called, came with a statement from Allergan saying that it believes "current circumstances warrant that we depart from our established corporate policy of not commenting on market rumors and speculation concerning acquisitions and mergers [this one arising from a Wall Street Journal article]. We have been in discussions with P&U regarding a possible combination of our companies." Allergan went on to note that "the discussions involved a possible stock-for-stock merger with pooling of interest accounting treatment," which are not feasible, and the discussions have thus been terminated.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze